Pancreas transplantationNo Induction Versus Anti-IL2R Induction Therapy in Simultaneous Kidney Pancreas Transplantation: A Comparative Analysis
Section snippets
Study Design
Between January 2001 and April 2004, 63 SKPT cases met criteria for inclusion in the study. Patients were divided into two groups: no induction group of 42 patients and anti-IL-2R induction group of 21 SKPT using anti IL-2 receptor monoclonal antibody (two doses of 2 mg/kg daclizumab [Zenapax, Roche], or two doses of 20 mg basiliximab [Simulect, Novartis]). We excluded retransplants; recipients who received induction therapy with monoclonal or polyclonal antilymphocyte preparations; and
Demographics
Table 1 shows the clinical characteristics of the SKPT recipients. Patient age at transplantation, duration of diabetes prior to transplantation, percentage of patients on dialysis, and duration of dialysis prior to transplantation were similar between the groups. Enteric exocrine drainage was performed in 38 patients in the no induction group (90.4%) and 15 patients (71.4%) in the anti-IL-2R induction group (P = NS). The incidence of delayed graft function was also similar in both groups.
Acute Rejection Episodes
In
Discussion
The present study analyzed the safety and efficacy of a no induction protocol compared with anti-IL-2R induction among type 1 diabetic patients undergoing SKPT and receiving the same maintenance immunosuppressive regimen. Our first objective was to analyze whether there was a difference in the incidence of acute rejection episodes in both protocols. The results observed in this study showed equal 1-year acute rejection incidences in both no induction and anti-IL-2R induction cohorts. These
Acknowledgments
We thank Natascha Kim Camaroske for her assistance in database management.
References (7)
Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipientsa multi-center report
Transplant Proc
(1997)- et al.
The Banff 97 working classification of renal allograft pathology
Kidney Int
(1999) - et al.
One-year outcomes in simultaneous kidney–pancreas transplant recipients receiving an alternative dosing regimen of daclizumab
Transplant Proc
(2004)
Cited by (10)
A Single-center Experience on the Value of Pancreas Graft Biopsies and HLA Antibody Monitoring after Simultaneous Pancreas-Kidney Transplantation
2015, Transplantation ProceedingsCitation Excerpt :On the other hand, 1 patient with loss of DSA and normal kidney allograft function presented with signs of AMR of the pancreas allograft (C4d-positive). The cumulative 73% incidence of rejection after SPKT in our series is comparable to rejection rates in other reports [3,8,18–20]. Cantarovich et al recently found a 53.8% rejection rate of either kidney or pancreas allografts in a cohort of 40 patients with pancreas allograft biopsies and DSA monitoring [21].
Risk factors of pancreatic graft loss and death of receptor after simultaneous pancreas/kidney transplantation
2014, Transplantation ProceedingsCitation Excerpt :A prospective, randomized, multicenter study compared the use of antibody therapy with no induction therapy, and the outcome in the first year showed fewer episodes of rejection; however, in 3 years, there was no difference in survival in acute rejection episodes or morbidity [31]. The use of daclizumab induction (nondepleting agent) also was not associated with any change in graft or patient survival [32]. Becker et al compared induction therapy using basiliximab or daclizumab with immunosuppressive therapy without induction, for combined pancreas/kidney modality.
Induction and immunosuppressive management of pancreas transplant recipients
2020, Current Pharmaceutical DesignImmunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: Review and perspective
2014, Expert Review of Clinical ImmunologyTrends in immunosuppression after pancreas transplantation: What is in the pipeline?
2013, Current Opinion in Organ Transplantation